Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in heart failure with preserved ejection fraction and pulmonary vascular disease (Phase 2b)
2016-003653-15Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) comparing Macitentan 10 mg with Placebo (2 arms). Primary endpoint: Change in NT-proBNP at Week 24. Started Feb 2017; status: completed.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on 2016-003653-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003653-15.